IMR Press / FBL / Volume 13 / Issue 16 / DOI: 10.2741/3144

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Genetic manipulation of islet cells in autoimmune diabetes: from bench to bedside
Show Less
1 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
2 Department of Surgery, National Defense Medical Center, Taipei, Taiwan, ROC
3 Department of Medical Research, Tri-Service General Hospital, Taipei, Taiwan, ROC
Academic Editor:Myung-Shik Lee
Front. Biosci. (Landmark Ed) 2008, 13(16), 6155–6169; https://doi.org/10.2741/3144
Published: 1 May 2008
(This article belongs to the Special Issue Recent progress in signal transduction of islet beta cells)
Abstract

Type 1 diabetes (T1D) develops via spontaneous autoimmune destruction of pancreatic beta cells. The immunoprogression and effectors of T1D have been determined using non-obese diabetic (NOD) mouse mode. Transgenic mice overexpressing a variety of transgenes driven by insulin promoter demonstrate that both apoptosis and necrosis lead to islet cells death; furthermore, various immune cells and cytokine effectors are involved in the immunoprogression of T1D. Efficiently halting immune attack in the islet milieu by an effector-specific manner apparently provides the preventive and therapeutic strategies in T1D. Islet transplantation has been reported as an appropriate treatment to accomplish insulin independence and long-term homeostasis of glucose in T1D. However, it is difficult to protect the islet grafts from subsequent immune attack and prolong their survival. In this review, we highlight the transgenic mice that express transgenes restricted in islet cells to depict the complicated interactions of immune cells in inflammatory islets, to investigate the protective efficacy of some immunomodulatory genes, and to develop genetically-modified islets tolerant to immune attack that might be used in future clinical application.

Share
Back to top